Publications
Detailed Information
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Lee, Jong-Seok | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Han, Hyesun | - |
dc.contributor.author | Kim, Woo Ho | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2020-04-27T11:01:26Z | - |
dc.date.available | 2020-04-27T11:01:26Z | - |
dc.date.created | 2018-12-11 | - |
dc.date.created | 2018-12-11 | - |
dc.date.created | 2018-12-11 | - |
dc.date.created | 2018-12-11 | - |
dc.date.issued | 2018-07 | - |
dc.identifier.citation | Cancer Research and Treatment, Vol.50 No.3, pp.835-842 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.other | 70946 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165226 | - |
dc.description.abstract | Purpose Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity against wild type of epidermal growth factor receptor (EGFR) family kinases including EGFR, HER2, and HER4 and EGFR-mutant cells in vitro. Two phase I studies were conducted to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity against advanced solid tumors. Materials and Methods Standard 3+3 dose escalation scheme using two different dosing schedules were studied: once daily, 14-day on, and 7-day off (intermittent schedule); and once daily continuous dosing with food effect. Additional patients were enrolled in an expansion cohort. Results A total of 75 patients were enrolled in the two studies. The most common drug-related treatment-emergent adverse events were diarrhea, rash, stomatitis, pruritus, and anorexia. Dose-limiting toxicities were grade 3 diarrhea in the intermittent schedule and grade 3 anorexia and diarrhea in the continuous dosing schedule. The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule. Eight (16%) and 24 (47%) of 51 evaluable patients in the intermittent schedule achieved partial response (PR) and stable disease (SD), respectively. Four (21%) and six (32%) of 19 evaluable patients in continuous dosing schedule achieved PR and SD, respectively. Patients with PR (n=7) or SD. 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer). Conclusion Poziotinib was safe and well tolerated in patients with advanced solid tumors. It showed an encouraging activity against EGFR-mutant and HER2-amplified cancers. | - |
dc.language | 영어 | - |
dc.publisher | 대한암학회 | - |
dc.title | Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.4143/crt.2017.303 | - |
dc.citation.journaltitle | Cancer Research and Treatment | - |
dc.identifier.wosid | 000438332100021 | - |
dc.identifier.scopusid | 2-s2.0-85049801906 | - |
dc.citation.endpage | 842 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 835 | - |
dc.citation.volume | 50 | - |
dc.identifier.sci | 000438332100021 | - |
dc.identifier.kciid | ART002366784 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Lee, Jong-Seok | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Woo Ho | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | OVERCOME RESISTANCE | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | HM781-36B | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | AFATINIB | - |
dc.subject.keywordAuthor | EGFR mutation | - |
dc.subject.keywordAuthor | HER2 amplification | - |
dc.subject.keywordAuthor | Poziotinib | - |
dc.subject.keywordAuthor | Non-small-cell lung carcinoma | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.